Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 17/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | WNT3A | P56704 | 1/20 | 0.46 |
| ▸ | GPR183 | P32249 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4620287 | 0.88 | CFTR (0.44) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL26573820 | 0.88 | CFTR (0.44) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL10066075 | 0.86 | CFTR (0.50) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL15679265 | 0.86 | CFTR (0.48) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL724752 | 0.86 | CFTR (0.51) | CFTR | |
| SCHEMBL1464755 | 0.84 | CYP2C19 (0.42) | CFTRCYP2C9 | |
| SCHEMBL12283199 | 0.84 | CFTR (0.46) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL17029841 | 0.84 | CFTR (0.42) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL12286746 | 0.83 | CFTR (0.47) | CFTRCTNNB1WNT3A | |
| SCHEMBL16110568 | 0.83 | CFTR (0.48) | CFTRCTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3219709-B1 | INTERMEDIATE COMPOUND OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2020-03-18 | — | — | EP | claimed |
| CN-107033120-B | Preparation method of 2- (2, 2-difluorobenzo [ D ] [1,3] dioxol-5-yl) acetonitrile | 苏州旺山旺水生物医药有限公司 | 2020-03-17 | — | — | CN | claimed |
| EP-3219709-A1 | INTERMEDIATE COMPOUND OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2017-09-20 | — | — | EP | claimed |
| US-20260108506-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED | 2026-04-23 | — | — | US | disclosed |
| US-20260092047-A1 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMA (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4218754-B1 | VANZACAFTOR FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4648753-B1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | VERTEX PHARMA (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260034064-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | VERTEX PHARMA (US) | 2026-02-05 | — | — | US | disclosed |
| EP-3634402-B1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12508231-B2 | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4648753-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2025-11-19 | — | — | EP | disclosed |
| WO-2007117715-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007087066-A2 | 1-(BENZO [D] [1,3] DI0X0L-5-YL) -N- (PHENYL) CYCLOPROPANE- CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS FOR THE TREATMENT OF CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007056341-A1 | HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056341-A1 | HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007021982-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007021982-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1716122-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060052358-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), such as N-(4,5-Diphenyl-thiazol-2-yl)-benzamide, used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-03-09 | — | — | US | disclosed |
| WO-2005075435-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108506-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, CLCN2, SCNN1B | CFTR 1/4885NR1I2 566/4885ADORA3 943/4885 |
| US-20260092047-A1 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | CFTR, SLC26A3, SLC26A4 | CFTR 1/4885NR1I2 950/4885ADORA3 587/4885 |
| US-20060052358-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), such as N-(4,5-Diphenyl-thiazol-2-yl)-benzamide, used for treating genetic disorders; respiratory system disorders | CFTR, ABCC2, ABCC4 | CFTR 1/4885NR1I2 506/4885ADORA3 373/4885 |
| US-20260034064-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | CFTR, ABCC2, ABCC8 | CFTR 1/4885NR1I2 1207/4885ADORA3 496/4885 |
| US-12508231-B2 | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | CFTR, MFAP1, CMA1 | CFTR 1/4885NR1I2 3453/4885ADORA3 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.